GlassScriptPhysician profile
James William Montag
NPI 1760520159
$4,351.85
in general payments reported to CMS, 2019-2025
18 companies · $958 in 2025
The $958 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.36 · 2021: $1,016 · 2022: $661 · 2023: $691 · 2024: $937 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.53 | 2021-2024 | |
| Novo Nordisk INC | $965.95 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $685.88 | 2021-2025 | Farxiga, Tezspire, Airsupra |
| Lilly USA, LLC | $406.68 | 2021-2025 | Mounjaro |
| Abbott Laboratories | $149.95 | 2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $123.84 | 2025 | |
| Acadia Pharmaceuticals INC | $121.45 | 2025 | Nuplazid |
| Sanofi-Aventis U.S. LLC | $117.17 | 2023 | |
| Lundbeck LLC | $114.08 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $110.99 | 2024 | Arexvy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.43 | 2024 | |
| Pacira Therapeutics, INC. | $89.36 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.42 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $82.26 | 2023 | Abilify Asimtufii, Abilify Maintena |
| Merck Sharp & Dohme LLC | $62.91 | 2023 | Verquvo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $57.59 | 2021 | |
| Insulet Corporation | $51.24 | 2024 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $26.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Montag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.